METACARDIS
Metagenomics in Cardiometabolic Diseases
| Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 23˙120˙429 € |
| EC contributo | 11˙999˙992 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2017-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | coordinator | 2˙512˙788.00 |
| 2 |
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
Organization address
address: Rue De L'Universite 147 contact info |
FR (PARIS CEDEX 07) | participant | 2˙649˙374.00 |
| 3 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 1˙151˙649.80 |
| 4 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 911˙396.00 |
| 5 | KOBENHAVNS UNIVERSITET | DK | participant | 900˙050.00 |
| 6 |
UNIVERSITAET LEIPZIG
Organization address
address: RITTERSTRASSE 26 contact info |
DE (LEIPZIG) | participant | 715˙480.00 |
| 7 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 699˙999.00 |
| 8 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | participant | 551˙590.00 |
| 9 |
CHALMERS TEKNISKA HOEGSKOLA AB
Organization address
address: - contact info |
SE (GOETEBORG) | participant | 550˙000.00 |
| 10 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 540˙000.00 |
| 11 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 496˙328.00 |
| 12 |
DANONE RESEARCH
Organization address
address: Route Departementale 128 contact info |
FR (PALAISEAU) | participant | 159˙400.00 |
| 13 |
BIOBYTE SOLUTIONS GMBH
Organization address
address: Bothestrasse 142 contact info |
DE (Heidelberg) | participant | 142˙937.20 |
| 14 |
CARGILL HAUBOURDIN SAS
Organization address
address: RUE DU MARECHAL JOFFRE 7 contact info |
FR (HAUBOURDIN) | participant | 19˙000.00 |
| 15 |
INST CARDIOMETABOLISME NUTRITION ICAN
Organization address
address: BOULEVARD DE L'HOPITAL 47-83 contact info |
FR (PARIS) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution.
METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD.
We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.'